GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tebentafusp   Click here for help

GtoPdb Ligand ID: 7378

Synonyms: IMCgp100 | Kimmtrak® | tebentafusp-tebn
Approved drug Immunopharmacology Ligand
tebentafusp is an approved drug (FDA & EMA (2022))
Compound class: Antibody
Comment: Tebentafusp (IMCgp100) is an immunotherapeutic antibody/peptide fusion, comprising a soluble T cell receptor (TCR) specific for the HLA-A2 restricted melanoma-associated antigen gp100, fused to an anti-CD3 single chain antibody fragment (scFv) [1,3-4]. This belongs to a novel class of immunotherapeutics termed ImmTACs (Immune Mobilising mTCR against Cancer) which are designed to restore immune surveillance and T-cell-directed killing of specific cancer cells.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. EU EMA (2022)  |  US FDA (2022)
International Nonproprietary Names Click here for help
INN number INN
10664 tebentafusp
Synonyms Click here for help
IMCgp100 | Kimmtrak® | tebentafusp-tebn
Database Links Click here for help
GtoPdb PubChem SID 178103950
PubChem SID 178103950
Search PubMed clinical trials tebentafusp
Search PubMed titles tebentafusp
Search PubMed titles/abstracts tebentafusp